Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
💡 한 문장 핵심
이중 5alpha-reductase 억제제인 dutasteride에 의한 양성전립선비대증 남성에서의 dihydrotestosterone의 현저한 억제.
5/5 보강
TL;DR
Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
399 patients with BPH were randomized to receive once-daily dosing for 24 wk of dutasteride (0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Mean testosterone levels increased but remained in the normal range for all treatment groups. Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo.
📑 코퍼스 인용 관계
· 인용됨 42
📑 인용한 논문 (6) ▾
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Be… Medicina (Kaunas, Lithuania) · 2025
- Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finast… The AAPS journal · 2025
- The Future of Alopecia Treatment: Plant Extracts, Nanocarriers, and 3D Bioprinting in Focu… Pharmaceutics · 2025
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Frontiers in pharmacology · 2025
- Development of Ethosomes for the Topical Treatment of Androgenic Alopecia: Ethanol Effect … Pharmaceutics · 2025
- A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the S… Cureus · 2025
연도별 인용 (2012–2026) · 합계 298
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Hormonal and reproductive studies
Prostate Cancer Diagnosis and Treatment
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
이중 5알파환원효소(5alpha-reductase) 억제제인 두타스테리드(dutasteride)가 제2형 선택적 억제제인 피나스테리드(finasteride)보다 혈청 디하이드로테스토스테론(DHT) 농도를 더 효과적으로 억제하는지 양성전립선비대증(BPH) 환자를 대상으로 검증하고자 하였다.
【방법】
BPH 환자 399명을 무작위 배정하여 24주간 1일 1회 두타스테리드(0.01, 0.05, 0.5, 2.5, 5.0 mg), 피나스테리드 5 mg, 또는 위약을 투여하고 혈청 DHT 및 테스토스테론 변화를 비교하였다.
【주요 결과】
두타스테리드 5.0 mg군은 DHT를 평균 98.4±1.2%, 0.5 mg군은 94.7±3.3% 감소시켜 피나스테리드 5 mg군의 70.8±18.3%보다 유의하게 강력하고 일관된 억제 효과를 보였다(P<0.001). 테스토스테론은 상승하였으나 정상 범위 내였고, 이상반응은 위약군과 유사하였다.
【임상적 시사점 (성형외과 의사 관점)】
DHT는 모낭과 피지선 내 안드로겐성 탈모(androgenetic alopecia) 및 피지 분비의 핵심 매개체로, 두타스테리드의 1형·2형 동시 억제는 두피 모낭에 풍부한 1형 효소까지 차단하여 피나스테리드 대비 더 강력한 DHT 억제를 기대할 수 있다. 모발이식(hair transplantation) 전후 보조요법이나 피나스테리드 반응 부족 남성형 탈모 환자에서 off-label 옵션으로 고려할 수 있으나, 한국 내 탈모 적응증 미허가 상태와 긴 반감기에 따른 가임기 남성 정자 노출·기형 위험에 대한 사전 상담이 필수적이다.
Dihydrotestosterone (DHT) is the primary metabolite of testosterone in the prostate and skin. Testosterone is converted to DHT by 5alpha-reductase, which exists in two isoenzyme forms (types 1 and 2). DHT is associated with development of benign prostatic hyperplasia (BPH), and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery. A selective inhibitor of the type 2 isoenzyme (finasteride) has been shown to decrease serum DHT by about 70%. We hypothesized that inhibition of both isoenzymes with the dual inhibitor dutasteride would more effectively suppress serum DHT levels than selective inhibition of only the type 2 isoenzyme. A total of 399 patients with BPH were randomized to receive once-daily dosing for 24 wk of dutasteride (0.01, 0.05, 0.5, 2.5, or 5.0 mg), 5 mg finasteride, or placebo. The mean percent decrease in DHT was 98.4 +/- 1.2% with 5.0 mg dutasteride and 94.7 +/- 3.3% with 0.5 mg dutasteride, significantly lower (P < 0.001) and with less variability than the 70.8 +/- 18.3% suppression observed with 5 mg finasteride. Mean testosterone levels increased but remained in the normal range for all treatment groups. Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo.
- p-value P < 0.001
【연구 목적】 이중 5알파환원효소(5alpha-reductase) 억제제인 두타스테리드(dutasteride)가 제2형 선택적 억제제인 피나스테리드(finasteride)보다 혈청 디하이드로테스토스테론(DHT) 농도를 더 효과적으로 억제하는지 양성전립선비대증(BPH) 환자를 대상으로 검증하고자 하였다.
APA 7
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.. The Journal of clinical endocrinology and metabolism, 89(5), 2179-84. https://doi.org/10.1210/jc.2003-030330
Vancouver
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Jour. clin. endo. meta.. 2004;89(5):2179-84. doi:10.1210/jc.2003-030330
AMA 11
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Jour. clin. endo. meta.. 2004;89(5):2179-84. doi:10.1210/jc.2003-030330
Chicago
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., and Hobbs, S.. 2004. "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor." The Journal of clinical endocrinology and metabolism 89 (5): 2179-84. https://doi.org/10.1210/jc.2003-030330
MLA 9
Clark, R. V., et al. "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor." The Journal of clinical endocrinology and metabolism, vol. 89, no. 5, 2004, pp. 2179-84. doi:10.1210/jc.2003-030330.
PMID
15126539 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Androgenetic Alopecia: Therapy Update.
- Androgenetic Alopecia: An Update of Treatment Options.
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic a…
- Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
- Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.
- The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia.
- Post-finasteride syndrome: An emerging clinical problem.
- Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
- The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
- Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of…
- Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgeni…
- Performance of Dutasteride-Nanostructured Lipid Carriers Coated with Lauric Acid-Chitosan Oligomer …
- Hormonal therapy in female pattern hair loss.
- Comparison of clinical trials with finasteride and dutasteride.
- The Future of Alopecia Treatment: Plant Extracts, Nanocarriers, and 3D Bioprinting in Focus.
- Bioengineered polyester nanoparticles for the synergistic treatment of androgenic alopecia the supp…
- The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia…
- Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kina…
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 미국 임상내분비학회, 미국 내분비학회, 안드로겐 과다 및 PCOS 학회 질환 임상 리뷰: 다낭성 난소 증후군의 평가와 치료를 위한 최선의 진료 지침--1부.
- 외인성 testosterone(T) 단독 또는 finasteride 병용 투여는 혈청 T가 낮은 고령 남성에서 신체 수행 능력, 악력 및 제지방량을 증가시킨다.
- 폐경전 여성의 다모증 평가 및 치료: Endocrine Society 임상진료지침.
- 남성 안드로겐성 탈모.